Cisapride in functional dyspepsia in general practice. A placebo-controlled, randomized, double-blind study

被引:36
作者
deGroot, GH
DeBoth, PSM
机构
[1] Department of Internal Medicine, Rode Kruis Ziekenhuis, Beverwijk
关键词
D O I
10.1046/j.1365-2036.1997.117288000.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Functional dyspepsia is recognized as a common disorder in clinical practice, The aim of this study was to determine the efficacy and adverse effects of cisapride compared to a placebo in patients from a general practice with functional dyspepsia (FD), Secondly we investigated whether Helicobacter pylori-positive FD patients present with specific symptoms and determined the efficacy of cisapride for FD patients with Methods: In a placebo-controlled double-blind study, patients were randomized to receive fixed doses of either cisapride (10 mg three times daily) or placebo, Symptoms were evaluated after 2 and 4 weeks of treatment. The selection of FD patients,collection of data, and evaluation of symptoms as well as adverse effects were performed by general practitioners, Dyspeptic patients were referred to the Gastroenterology Department in order to exclude ulcers, oesophagitis, pancreatitis and gallstones, Biopsies of gastric mucosa were taken for histological examination and H. pylori culture, Patients: 121 patients entered this study (61 took cisapride, 60 placebo), There were 113 patients (56 cisapride, 57 placebo) available for analysis of the efficacy and 120 patients (61 cisapride, 59 placebo) for evaluation of adverse effects,In total 102 biopsies were tested for the presence of gastritis by histological examination, There were 30 H. pylori-positive cultures among 111 patients. Results: After 4 weeks a statistically significant reduction in symptoms was found, but it was similar in the two groups, No symptoms specific for H. pylori-positive patients were found, There was not a significant difference in the response to cisapride between H. pylori-positive and H. pylori-negative patients. The difference in overall (63%) response in the cisapride group and the 44% response in the placebo group did not reach statistical significance. Conclusions: No significant difference was found between placebo and cisapride in the treatment of FD in general practice, H. pylori-positive patients did not present with specific symptoms nor did they exhibit a different response to cisapride.
引用
收藏
页码:193 / 199
页数:7
相关论文
共 56 条
  • [21] EPIDEMIOLOGY OF CAMPYLOBACTER-PYLORI INFECTION - ETHNIC CONSIDERATIONS
    GRAHAM, DY
    KLEIN, PD
    OPEKUN, AR
    BOUTTON, TW
    EVANS, DJ
    EVANS, DG
    ALPERT, LC
    MICHALETZ, PA
    YOSHIMURA, HH
    ADAM, E
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1988, 23 : 9 - 13
  • [22] GREGSON DB, 1989, CAN MED ASSOC J, V140, P1449
  • [23] HANNON R, 1987, CURR THER RES CLIN E, V42, P814
  • [24] CISAPRIDE TREATMENT OF PATIENTS WITH NONULCER DYSPEPSIA AND EROSIVE PREPYLORIC CHANGES - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    HAUSKEN, T
    BERSTAD, A
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1992, 27 (03) : 213 - 217
  • [25] DEFINITIONS OF DYSPEPSIA
    HEADING, RC
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1991, 26 : 1 - 6
  • [26] FACTORS AFFECTING SHORT-TERM AND LONG-TERM OUTCOME OF A SHORT THERAPEUTIC TRIAL WITH CISAPRIDE IN DYSPEPTIC PATIENTS
    HEYSE, PM
    RAMBALDO, R
    HAZELHOFF, B
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1993, 28 : 15 - 24
  • [27] SYMPTOMATIC, RADIONUCLIDE AND THERAPEUTIC ASSESSMENT OF CHRONIC IDIOPATHIC DYSPEPSIA - A DOUBLE-BLIND PLACEBO-CONTROLLED EVALUATION OF CISAPRIDE
    JIAN, R
    DUCROT, F
    RUSKONE, A
    CHAUSSADE, S
    RAMBAUD, JC
    MODIGLIANI, R
    RAIN, JD
    BERNIER, JJ
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1989, 34 (05) : 657 - 664
  • [28] MEASUREMENT OF GASTRIC-EMPTYING IN DYSPEPTIC PATIENTS - EFFECT OF A NEW GASTROKINETIC AGENT (CISAPRIDE)
    JIAN, R
    DUCROT, F
    PIEDELOUP, C
    MARY, JY
    NAJEAN, Y
    BERNIER, JJ
    [J]. GUT, 1985, 26 (04) : 352 - 358
  • [29] Johnsen R, 1988, Scand J Prim Health Care, V6, P239, DOI 10.3109/02813438809009324
  • [30] JONES DM, 1984, J CLIN PATHOL, V37, P1022